Current:Home > MarketsGlen Powell responds to rumor that he could replace Tom Cruise in 'Mission: Impossible' -AdvancementTrade
Glen Powell responds to rumor that he could replace Tom Cruise in 'Mission: Impossible'
View
Date:2025-04-18 11:52:34
Glen Powell could never take the place of Tom Cruise.
The "Twisters" actor responded to rumors that the action star wanted Powell to replace him in the "Mission: Impossible" franchise when Pat McAfee called him up live on his ESPN show Tuesday.
Powell, who McAfee didn't show on camera because the actor was in costume filming his new movie "The Running Man," was asked if the rumor was true.
"We just want to call and say congratulations, brother," McAfee told Powell. But the actor seemed to rebut the rumor in jest: "My mom would never let me do that."
Powell, 36, also playfully rejected the idea of doing his own Cruise-level stunts. "That's the worst gig in town, everybody knows that. That's a death trap."
Need a break? Play the USA TODAY Daily Crossword Puzzle.
Powell has become an action star in his own right, in recent films like "Twisters," which saw the actor play adrenaline-jacked storm chaser Tyler Owens, and "Hit Man," where he played Gary Johnson, a fake assassin for hire.
And he starred in "Top Gun: Maverick" alongside Cruise as Lt. Jake "Hangman" Seresin in 2022. Powell, a superfan of the original "Top Gun," made a social media stir years prior when he admitted he lost out on the coveted role of the late Nick "Goose" Bradshaw's son. Amid the public crash and burn, Cruise (as Pete "Maverick" Mitchell) created the even-flashier "Maverick" role of irresistible bad-boy pilot Hangman.
Powell is set to star in the dystopian science fiction film "The Running Man," directed by Edgar Wright and also starring Josh Brolin, based on the Stephen King novel.
For his part, Cruise, 62, has not slowed down. The actor starred in 2023's "Mission: Impossible – Dead Reckoning Part One," which saw him continue to perform outrageous stunts. He's gearing up for the franchise's eighth installment, "Mission: Impossible – The Final Reckoning," set to be released in 2025.
Contributing: Bryan Alexander
veryGood! (44455)
Related
- Realtor group picks top 10 housing hot spots for 2025: Did your city make the list?
- Turning Skiers Into Climate Voters with the Advocacy Potential of the NRA
- Jana Kramer Engaged to Allan Russell: See Her Ring
- Two and a Half Men's Angus T. Jones Is Unrecognizable in Rare Public Sighting
- Justice Department, Louisville reach deal after probe prompted by Breonna Taylor killing
- Virtually ouch-free: Promising early data on a measles vaccine delivered via sticker
- Vanderpump Rules' Tom Sandoval Claims His and Ariana Madix's Relationship Was a Front
- Building Emissions Cuts Crucial to Meeting NYC Climate Goals
- Have Dry, Sensitive Skin? You Need To Add These Gentle Skincare Products to Your Routine
- Ariana Madix Claims Tom Sandoval and Raquel Leviss Had Sex in Her Guest Room While She Was Asleep
Ranking
- As Trump Enters Office, a Ripe Oil and Gas Target Appears: An Alabama National Forest
- Here's what's on the menu for Biden's state dinner with Modi
- Legendary Singer Tina Turner Dead at 83
- One man left Kansas for a lifesaving liver transplant — but the problems run deeper
- NFL Week 15 picks straight up and against spread: Bills, Lions put No. 1 seed hopes on line
- Why Kourtney Kardashian and Travis Barker Are Officially Done With IVF
- As Covid-19 Surges, California Farmworkers Are Paying a High Price
- Victorian England met a South African choir with praise, paternalism and prejudice
Recommendation
Brianna LaPaglia Reveals The Meaning Behind Her "Chickenfry" Nickname
Once 'paradise,' parched Colorado valley grapples with arsenic in water
Deaths of American couple prompt luxury hotel in Mexico to suspend operations
Duke Energy Takes Aim at the Solar Panels Atop N.C. Church
The FTC says 'gamified' online job scams by WhatsApp and text on the rise. What to know.
Exxon Ramps Up Free Speech Argument in Fighting Climate Fraud Investigations
Think the COVID threat is over? It's not for these people
FDA advisers narrowly back first gene therapy for muscular dystrophy